Loading clinical trials...
Loading clinical trials...
Safety of a Real-time Continuous Glucose Monitor-based Insulin Bolus Calculator: The "CGM-IBC" Study B
This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor.
Individuals with type 1 diabetes and those with type 2 diabetes who are prescribed bolus insulin must decide on an insulin dose for any given meal. This dose is often based on what they are eating and their glucose value. Insulin bolus calculators may be helpful in recommending an insulin dose. This study examines the safety of an app-based insulin calculator manufactured by Welldoc (Columbia, MD). This app uses the glucose value and trend arrow, in certain circumstances, to recommend a bolus insulin dose. This study is a single arm trial where continuous glucose monitoring metrics such as time in range will be measured before and after the study participants are given the app.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
MedStar Health Research Institute
Baltimore, Maryland, United States
Start Date
July 5, 2022
Primary Completion Date
December 20, 2022
Completion Date
December 20, 2022
Last Updated
March 17, 2023
27
ACTUAL participants
BlueStar 10
DEVICE
Lead Sponsor
Welldoc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07480161